D
David H. Kirn
Researcher at University of Oxford
Publications - 158
Citations - 20389
David H. Kirn is an academic researcher from University of Oxford. The author has contributed to research in topics: Oncolytic virus & Cancer. The author has an hindex of 66, co-authored 153 publications receiving 19336 citations. Previous affiliations of David H. Kirn include Imperial College London & Queen Mary University of London.
Papers
More filters
Journal ArticleDOI
An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.
James R. Bischoff,David H. Kirn,Angelica Williams,Carla Heise,Sharon Horn,Mike Muna,Lelia Ng,Julie Nye,Adam Sampson-Johannes,Ali Fattaey,Frank McCormick +10 more
TL;DR: Injection of the mutant virus into p53-deficient human cervical carcinomas grown in nude mice caused a significant reduction in tumor size and caused complete regression of 60 percent of the tumors, raising the possibility that mutant adenoviruses can be used to treat certain human tumors.
Journal ArticleDOI
A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
Fadlo R. Khuri,John Nemunaitis,Ian Ganly,James Arseneau,Ian F. Tannock,Larry Romel,Martin Gore,J. Ironside,Robert Hugh MacDougall,Carla Heise,Britta Randlev,Ann M. Gillenwater,Patricia A. Bruso,Stanley B. Kaye,Waun Ki Hong,David H. Kirn +15 more
TL;DR: A phase II trial of a combination of intratumoral ONYX-015 injection with cisplatin and 5-fluorouracil in patients with recurrent squamous cell cancer of the head and neck found substantial objective responses, including a high proportion of complete responses.
Journal ArticleDOI
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
Carla Heise,Adam Sampson-Johannes,Angelica Williams,Frank McCormick,D D Von Hoff,David H. Kirn +5 more
TL;DR: It is reported that normal human cells were highly resistant to ONYX-015-mediated, replication-dependent cytolysis and a wide range of human tumor cells, including numerous carcinoma lines with either mutant or normal p53 gene sequences, were efficiently destroyed.
Journal ArticleDOI
An essential role for Rac in Ras transformation
TL;DR: It is shown that Ratl fibroblasts expressing activated Val-12 Racl (Racl with valine at residue 12) display all the hallmarks of malignant transformation and that Rac is essential for transformation by Ras, indicating that oncogenic Ras drives both the Rac and MAP-kinase pathways, which cooperate to cause transformation.
Journal ArticleDOI
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
Jeong Heo,Tony R. Reid,Leyo Ruo,Caroline J. Breitbach,Steven C. Rose,Mark Bloomston,Mong Cho,Ho Yeong Lim,Hyun Cheol Chung,Chang Won Kim,James M. Burke,Riccardo Lencioni,Theresa Hickman,Anne Moon,Yeon Sook Lee,Mi Kyeong Kim,Manijeh Daneshmand,Kara S DuBois,Lara Longpre,Minhtran C. Ngo,Cliona M. Rooney,John C. Bell,Byung Geon Rhee,Richard H. Patt,Tae-Ho Hwang,David H. Kirn +25 more
TL;DR: JX-594 demonstrated oncolytic and immunotherapy MOA, tumor responses and dose-related survival in individuals with HCC, and subject survival duration was significantly related to dose.